Epizyme (EPZM) Commences Dosing in Tazemetostat Phase 2 as Mesothelioma Treatment
Tweet Send to a Friend
Epizyme, Inc. (Nasdaq: EPZM) announced that the first patient has been dosed in the Company’s global phase 2 study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
